Particle Therapy to Overcome Cancer Radiation Resistance: "ARCHADE" Consortium Updates in Radiation Biology

Area of Science:

• Oncology
• Radiation Biology
• Medical Physics

Background:

• Radiation therapy uses high-dose radiation to damage cancer cell DNA.
• Radiotherapy is adaptable as a primary, adjuvant, or palliative treatment.
• Advancements aim to boost cancer cell kill rates and minimize healthy tissue damage.

Purpose of the Study:

• To evaluate the therapeutic advantages of hadron therapy based on tumor characteristics.
• To provide biological evidence supporting hadron therapy's efficacy.
• To present updated research from the ARCHADE association and the C400 accelerator.

Main Methods:

• Investigating proton and carbon ion therapy as alternatives to conventional radiotherapy.
• Analyzing the mechanisms by which hadrons spare healthy tissues (e.g., reduced lymphopenia, bystander effects).
• Exploring radiation biology to understand cancer cell radioresistance (hypoxia, DNA repair, stem cells) and normal tissue sensitivity.

Main Results:

• Proton and carbon ion therapy demonstrate potential in overcoming tumor radioresistance.
• Hadrons show reduced oxygen dependency and enhanced cancer stem cell killing.
• Hadrons effectively spare healthy tissues through various biological mechanisms.

Conclusions:

• Hadrons, including proton and carbon ion therapy, offer promising alternatives for cancer treatment.
• Technological improvements like image-guided radiotherapy and particle therapies enhance efficacy and safety.
• Continued research in radiation biology is crucial for optimizing targeted and safe radiotherapy.